The Relationship of Osteoprotegerin with Cardiovascular Risk Factors in Women with and Without Polycystic Ovary Syndrome

被引:1
作者
Aydin, Gultekin Adanas [1 ]
Ozsoy, Hilal Gulsum Turan [2 ]
机构
[1] Bursa Yuksek Ihtisas Training & Res Hosp, Clin Gynecol & Obstet, Bursa, Turkey
[2] Bursa Cekirge Publ Hosp, Clin Radiol, Bursa, Turkey
来源
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI | 2020年 / 58卷 / 03期
关键词
Osteoprotegerin; polycystic ovary syndrome; atherosclerosis; SOLUBLE RECEPTOR ACTIVATOR; KAPPA-B LIGAND; CIRCULATING OSTEOPROTEGERIN; ENDOTHELIAL DYSFUNCTION; INSULIN SENSITIVITY; METABOLIC SYNDROME; ARTERY-DISEASE; MORTALITY; DENSITY; EVENTS;
D O I
10.4274/haseki.galenos.2020.5840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: In this study, we aimed to compare osteoprotegerin (OPG) levels in patients with and without polycystic ovary syndrome (PCOS) and to investigate the correlation between OPG levels and cardiovascular risk factors. Methods: A total of 49 patients with PCOS and 31 age- and body mass index-matched healthy controls were included in the study. Blood samples were collected and hormonal and metabolic parameters and OPG levels were analyzed. The carotid intima-media thickness (CIMT) was measured for each patient and control through ultrasonography. Results: The low-density lipoprotein and total cholesterol levels were higher and the Homeostasis Model Assessment-Insulin Index (HOMA-IR) values were higher in patients with PCOS (p=0.002, p=0.037, and p=0.028, respectively). The OPG levels were 4.29 pmol/L and 4.07 pmol/L in the patient and control groups, respectively, indicating no significant difference between the groups. The CIMT was 0.57 in both groups. Conclusion: Our study results suggest that OPG levels appear to be similar in patients with PCOS and healthy controls. Although OPG has been associated with endothelial dysfunction, atherosclerosis and coronary calcification in previous studies, currently not a useful marker for cardiovascular risk analysis in this patient population.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 39 条
  • [1] No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome
    Abali, Remzi
    Tasdemir, Nicel
    Alpsoy, Seref
    Tasdemir, Ufuk Goker
    Guzel, Savas
    Yuksel, Mehmet Aytac
    Yuksel, Ilkbal Temel
    Yilmaz, Murat
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2015, 291 (05) : 1075 - 1080
  • [2] Osteoprotegerin:: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients
    Avignon, Antoine
    Sultan, Ariane
    Piot, Christophe
    Mariano-Goulart, Denis
    Dieudonné, Jean-Francois Thuan dit
    Cristol, Jean Paul
    Dupuy, Anne Marie
    [J]. DIABETES CARE, 2007, 30 (11) : 2934 - 2939
  • [3] The prevalence and features of the polycystic ovary syndrome in an unselected population
    Azziz, R
    Woods, KS
    Reyna, R
    Key, TJ
    Knochenhauer, ES
    Yildiz, BO
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) : 2745 - 2749
  • [4] Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker
    Barbu, Carmen G.
    Arsene, Andreea L.
    Florea, Suzana
    Albu, Alice
    Sirbu, Anca
    Martin, Sorina
    Nicolae, Alina C.
    Burcea-Dragomiroiu, George T. A.
    Popa, Daniela E.
    Velescu, Bruno S.
    Dumitrescu, Ion B.
    Mitrea, Niculina
    Draganescu, Doina
    Lupuliasa, Dumitru
    Spandidos, Demetrios A.
    Tsatsakis, Aristides M.
    Dragoi, Cristina M.
    Fica, Simona
    [J]. MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 6059 - 6067
  • [5] Osteoprotegerin: Multiple partners for multiple functions
    Baud'huin, Marc
    Duplomb, Laurence
    Teletchea, Stephane
    Lamoureux, Francois
    Ruiz-Velasco, Carmen
    Maillasson, Mike
    Redini, Francoise
    Heymann, Marie-Francoise
    Heymann, Dominique
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2013, 24 (05) : 401 - 409
  • [6] Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes
    Bernardi, Stella
    Fabris, Bruno
    Thomas, Merlin
    Toffoli, Barbara
    Tikellis, Christos
    Candido, Riccardo
    Catena, Cristiana
    Mulatero, Paolo
    Barbone, Fabio
    Radillo, Oriano
    Zauli, Giorgio
    Secchiero, Paola
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 394 (1-2) : 13 - 20
  • [7] Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women
    Browner, WS
    Lui, LY
    Cummings, SR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) : 631 - 637
  • [8] Human Full-Length Osteoprotegerin Induces the Proliferation of Rodent Vascular Smooth Muscle Cells both in vitro and in vivo
    Candido, Riccardo
    Toffoli, Barbara
    Corallini, Federica
    Bernardi, Stella
    Zella, Davide
    Voltan, Rebecca
    Grill, Vittorio
    Celeghini, Claudio
    Fabris, Bruno
    [J]. JOURNAL OF VASCULAR RESEARCH, 2010, 47 (03) : 252 - 261
  • [9] Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
    Diamanti-Kandarakis, Evanthia
    Dunaif, Andrea
    [J]. ENDOCRINE REVIEWS, 2012, 33 (06) : 981 - 1030
  • [10] Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome
    Escobar-Morreale, Hector F.
    Botella-Carretero, Jose I.
    Martinez-Garcia, M. Angeles
    Luque-Ramirez, Manuel
    Alvarez-Blasco, Francisco
    Millan, Jose L. San
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 159 (03) : 225 - 232